Purpose of Review Kratom (Mitragyna speciosa) is a psychoactive medicinal herb historically utilized in Southeast Asia for fatigue, pain, and various diseases.
Nevertheless, its rapid global expansion, particularly in Western consumer markets, has heightened regulatory scrutiny.
This narrative review examines the rapidly evolving global context of kratom legality, with a focus on major producing and consuming regions, and analyzes the factors and implications of varied regulatory responses.
Recent Findings The global regulatory trends for kratom were analyzed using a comparative and descriptive approach based on peer-reviewed studies, official reports, regulatory sources, news, and online materials up to early 2026. Kratom has been legalized and regulated in Thailand as an economic commodity, with sales restricted to at-risk populations.
In Malaysia, kratom is subject to strict poison control laws; however, there are ongoing discussions regarding potential reform. Indonesia’s regulatory framework is inconsistent, characterized by stringent internal constraints and export controls.
Hong Kong, a transit hub, has implemented stricter regulations regarding kratom alkaloids. In response to public opposition, federal efforts to schedule kratom in the United States were overturned, resulting in different state laws that range from consumer protection to prohibition. Various factors, including pharmacological considerations, scientific uncertainty, product variability, evolving use patterns, and indirect cannabis policy benchmarks, influence kratom policy.
Kratom regulation is heterogeneous across countries, reflecting differences in public health concerns, commercial interests, cultural traditions, scientific support, and regulatory views.
Given the ongoing scientific uncertainty and changing use patterns, kratom is likely to remain a matter for regulatory discussion, stressing the need for further study and evidence-based legislation.
Figures – available from: Current Addiction Reports
